Alnylam Pharmaceuticals Inc
(MEX:ALNY)
MXN
5899.69
0 (0%)
Market Cap: 699.59 Bil
Enterprise Value: 669.88 Bil
PE Ratio: 0
PB Ratio: 1,075.42
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023 / 08:40PM GMT
Release Date Price:
MXN3700
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Okay. Great. Good afternoon, everybody. Thanks for joining us. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad, I'm one of the senior SMid Biotech analysts here. It's my pleasure to have our next presenting company with me here on stage from Alnylam Pharmaceuticals. We've got Jeff Poulton, who is, of course, CFO; and also Eric Green, who is SVP and Head of Development Programs. So Eric and Jeff, thank you for making the trip out West.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
It's great to be here. Thank you.
Tazeen Ahmad;Jeffrey V. Poulton
BofA Securities, Research Division - MD in Equity Research & Research Analyst;Alnylam Pharmaceuticals,
So we usually ask everybody to give a 2-minute overview of their company, and then we go straight into Q&A. So I'll let Jeff take the honor of describing Alnylam in 2 minutes or less. .
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot